A Rising BIEL PPS Is the Master Key
Financing, Investors, and Strategic Buyers All Unlock at Once. For a microcap, nothing changes the company’s trajectory faster than a rising PPS. It is more than a number — it is access.
When BIEL’s PPS climbs, three doors swing open simultaneously:
1. Financing Becomes Cheaper, Faster, and More Strategic
A higher PPS dramatically improves:
access to institutional capital
leverage in negotiations
the ability to secure non-dilutive financing
terms on credit facilities
confidence from strategic partners
Instead of taking survival-mode funding, BIEL can pursue growth-mode financing that accelerates manufacturing, marketing, and retail expansion.
2. Serious Investors Finally Pay Attention
Microcaps are invisible until their PPS moves.
Once it does, the investor universe expands instantly:
microcap and small-cap growth funds
family offices
wellness-focused investment groups
crossover investors
med-tech and consumer-health specialists
These groups cannot justify entering a stagnant PPS — but they can justify entering a rising one.
3. Strategic Buyers Start Running the Numbers Large companies don’t acquire based on potential — they acquire based on momentum.
A rising PPS signals:
market validation
consumer traction
operational execution
reduced risk
increasing brand value
That’s when strategic buyers begin to take interest.
Logical, Realistic Potential Suitors for BIEL
These companies already operate in pain relief, consumer wellness, wearables, electroceuticals, digital health, or GLP-1-adjacent wellness.
Potential partners / acquirers include:
Johnson & Johnson — dominant in OTC pain relief; always seeking non-drug alternatives
Haleon (formerly GSK Consumer) — expanding into modern wellness categories
Perrigo — specializes in acquiring OTC brands with strong retail potential
Philips — major player in consumer health and connected devices
Withings — building a portfolio of medical-grade consumer wearables
Oura — expanding into pain, recovery, and wellness integrations
Garmin — increasingly focused on health metrics and recovery tech
Medtronic — heavily invested in neuromodulation and bioelectronic medicine
Boston Scientific — active in pain-management technologies
Abbott — expanding its wearable and sensor-based health ecosystem
Church & Dwight — known for acquiring high-margin consumer wellness brands
Prestige Consumer Healthcare — buys and scales OTC products with strong retail presence
Noom — building a GLP-1-adjacent wellness ecosystem
WeightWatchers — repositioning around GLP-1 and health tech
Hims & Hers — aggressively expanding into pain, wellness, and consumer health devices
A rising PPS makes BIEL acquirable, not just interesting.
Electrome ActiPatch: The Catalyst That Makes a PPS Breakout Possible
Before the internet, a microcap like BIEL had no path to mainstream visibility.
Today, a single spark — a PPS surge, a volume spike, an algorithmic trigger — can push a microcap into global financial news circulation in seconds.
Electrome’s ActiPatch launch is exactly that spark.
Why ActiPatch + Rising PPS Is a Publicity Engine
1. A Rebrand With Built-In Media Appeal
ActiPatch is shifting from “clinical device” to premium, tech-forward wellness hardware — the same playbook that turned wearables into a multibillion-dollar category.
Journalists get an instant storyline:
“Bioelectronic pain relief goes mainstream.”
“A medical-grade device gets a Silicon Valley makeover.”
“The next evolution of electroceuticals.”
A rising PPS makes this story newsworthy, not just interesting.
2. Electrome Fixes BIEL’s Historical Weakness: Visibility
For years, ActiPatch had elite science but weak retail presence.
Electrome changes that with:
countertop displays
floor stands
premium packaging
modern branding
This is the kind of operational shift analysts and journalists immediately recognize as a turning point.
A rising PPS validates that Ken Mayer’s strategy is working.
3. A Rising PPS Turns the Story Into a Global Headline. Financial media chases momentum, not press releases.
When BIEL’s PPS moves, algorithms react:
“Stocks on the move” alerts
Automated news blasts
Social media amplification
Momentum-trader coverage
And when they dig deeper, they find the Electrome ActiPatch transformation — a story tailor-made for coverage.
The PPS movement is the spark.
ActiPatch is the fuel.
Electrome is the engine.
The Electrome Partnership: The True Inflection Point
This isn’t incremental improvement — it’s a platform shift:
AI + bioelectronic medicine
GLP-1 wellness integration
wearable health tech
a massive installed base
a microcap with a big-tech narrative
A rising PPS makes this entire narrative credible, not theoretical.
The Loop That Turns BIEL Into a National Story. Once the PPS begins to rise:
news bots publish alerts
traders swarm
social media amplifies
analysts investigate
journalists write
retail investors discover
The cycle repeats.
Price = Coverage = Attention = Buying = More Coverage = Higher Price
This loop benefits:
BIEL, through increased market cap and financing leverage
Electrome, through elevated brand authority
Ken Mayer, through validation of execution and strategic vision
The Timing Could Not Be Better
BIEL now sits at the intersection of:
AI
GLP-1 wellness
bioelectronic medicine
predictive health
wearable technology
consumer wellness
public-market accessibility
This is exactly the kind of convergence financial media wants to write about.
All it needs is the spark — and nothing sparks faster than a PPS breakout.
Electrome ActiPatch Is the Catalyst.
A Rising PPS Is the Amplifier.
Together, They Can Turn BIEL From Overlooked to Unavoidable — and Potentially Into an Acquisition Target.
Financing, Investors, and Strategic Buyers All Unlock at Once. For a microcap, nothing changes the company’s trajectory faster than a rising PPS. It is more than a number — it is access.
When BIEL’s PPS climbs, three doors swing open simultaneously:
1. Financing Becomes Cheaper, Faster, and More Strategic
A higher PPS dramatically improves:
access to institutional capital
leverage in negotiations
the ability to secure non-dilutive financing
terms on credit facilities
confidence from strategic partners
Instead of taking survival-mode funding, BIEL can pursue growth-mode financing that accelerates manufacturing, marketing, and retail expansion.
2. Serious Investors Finally Pay Attention
Microcaps are invisible until their PPS moves.
Once it does, the investor universe expands instantly:
microcap and small-cap growth funds
family offices
wellness-focused investment groups
crossover investors
med-tech and consumer-health specialists
These groups cannot justify entering a stagnant PPS — but they can justify entering a rising one.
3. Strategic Buyers Start Running the Numbers Large companies don’t acquire based on potential — they acquire based on momentum.
A rising PPS signals:
market validation
consumer traction
operational execution
reduced risk
increasing brand value
That’s when strategic buyers begin to take interest.
Logical, Realistic Potential Suitors for BIEL
These companies already operate in pain relief, consumer wellness, wearables, electroceuticals, digital health, or GLP-1-adjacent wellness.
Potential partners / acquirers include:
Johnson & Johnson — dominant in OTC pain relief; always seeking non-drug alternatives
Haleon (formerly GSK Consumer) — expanding into modern wellness categories
Perrigo — specializes in acquiring OTC brands with strong retail potential
Philips — major player in consumer health and connected devices
Withings — building a portfolio of medical-grade consumer wearables
Oura — expanding into pain, recovery, and wellness integrations
Garmin — increasingly focused on health metrics and recovery tech
Medtronic — heavily invested in neuromodulation and bioelectronic medicine
Boston Scientific — active in pain-management technologies
Abbott — expanding its wearable and sensor-based health ecosystem
Church & Dwight — known for acquiring high-margin consumer wellness brands
Prestige Consumer Healthcare — buys and scales OTC products with strong retail presence
Noom — building a GLP-1-adjacent wellness ecosystem
WeightWatchers — repositioning around GLP-1 and health tech
Hims & Hers — aggressively expanding into pain, wellness, and consumer health devices
A rising PPS makes BIEL acquirable, not just interesting.
Electrome ActiPatch: The Catalyst That Makes a PPS Breakout Possible
Before the internet, a microcap like BIEL had no path to mainstream visibility.
Today, a single spark — a PPS surge, a volume spike, an algorithmic trigger — can push a microcap into global financial news circulation in seconds.
Electrome’s ActiPatch launch is exactly that spark.
Why ActiPatch + Rising PPS Is a Publicity Engine
1. A Rebrand With Built-In Media Appeal
ActiPatch is shifting from “clinical device” to premium, tech-forward wellness hardware — the same playbook that turned wearables into a multibillion-dollar category.
Journalists get an instant storyline:
“Bioelectronic pain relief goes mainstream.”
“A medical-grade device gets a Silicon Valley makeover.”
“The next evolution of electroceuticals.”
A rising PPS makes this story newsworthy, not just interesting.
2. Electrome Fixes BIEL’s Historical Weakness: Visibility
For years, ActiPatch had elite science but weak retail presence.
Electrome changes that with:
countertop displays
floor stands
premium packaging
modern branding
This is the kind of operational shift analysts and journalists immediately recognize as a turning point.
A rising PPS validates that Ken Mayer’s strategy is working.
3. A Rising PPS Turns the Story Into a Global Headline. Financial media chases momentum, not press releases.
When BIEL’s PPS moves, algorithms react:
“Stocks on the move” alerts
Automated news blasts
Social media amplification
Momentum-trader coverage
And when they dig deeper, they find the Electrome ActiPatch transformation — a story tailor-made for coverage.
The PPS movement is the spark.
ActiPatch is the fuel.
Electrome is the engine.
The Electrome Partnership: The True Inflection Point
This isn’t incremental improvement — it’s a platform shift:
AI + bioelectronic medicine
GLP-1 wellness integration
wearable health tech
a massive installed base
a microcap with a big-tech narrative
A rising PPS makes this entire narrative credible, not theoretical.
The Loop That Turns BIEL Into a National Story. Once the PPS begins to rise:
news bots publish alerts
traders swarm
social media amplifies
analysts investigate
journalists write
retail investors discover
The cycle repeats.
Price = Coverage = Attention = Buying = More Coverage = Higher Price
This loop benefits:
BIEL, through increased market cap and financing leverage
Electrome, through elevated brand authority
Ken Mayer, through validation of execution and strategic vision
The Timing Could Not Be Better
BIEL now sits at the intersection of:
AI
GLP-1 wellness
bioelectronic medicine
predictive health
wearable technology
consumer wellness
public-market accessibility
This is exactly the kind of convergence financial media wants to write about.
All it needs is the spark — and nothing sparks faster than a PPS breakout.
Electrome ActiPatch Is the Catalyst.
A Rising PPS Is the Amplifier.
Together, They Can Turn BIEL From Overlooked to Unavoidable — and Potentially Into an Acquisition Target.
2
